ALZAMEND NEURO, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
ALZAMEND NEURO, INC. (ALZN) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $1.39 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-09-10
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-07-31 was $1.39M, a 299.72% increase year-over-year.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-04-30 was -$511.18K.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-01-31 was $1.14M.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-10-31 was -$265.82K.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2026 was $711.39K.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$2.29M, a 4266.49% decline from fiscal 2024.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $54.94K, a 96.78% decline from fiscal 2023.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $1.71M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-07-31 | $1.39M 10-Q · filed 2026-09-10 | $882.05K derived: sum of 2 quarters · filed 2026-09-10 | $2.02M derived: sum of 3 quarters · filed 2026-09-10 | $1.76M derived: sum of 4 quarters · filed 2026-09-10 |
| 2026-04-30 | -$511.18K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | $628.66K derived: sum of 2 quarters · filed 2026-07-22 | $362.84K derived: sum of 3 quarters · filed 2026-07-22 | $711.39K 10-K · filed 2026-07-22 |
| 2026-01-31 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-11 | $874.02K derived: sum of 2 quarters · filed 2026-03-11 | $1.22M 10-Q · filed 2026-03-11 | $1.22M derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-10-31 | -$265.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-09 | $82.73K 10-Q · filed 2025-12-09 | $79.02K derived: sum of 3 quarters · filed 2026-09-10 | -$537.26K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-07-31 | $348.55K 10-Q · filed 2026-09-10 | $344.84K derived: sum of 2 quarters · filed 2026-09-10 | -$271.44K derived: sum of 3 quarters · filed 2026-09-10 | -$1.90M derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-04-30 | -$3.71K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | -$619.99K derived: sum of 2 quarters · filed 2026-07-22 | -$2.25M derived: sum of 3 quarters · filed 2026-07-22 | -$2.29M 10-K · filed 2026-07-22 |
| 2025-01-31 | -$616.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-11 | -$2.24M derived: sum of 2 quarters · filed 2026-03-11 | -$2.29M 10-Q · filed 2026-03-11 | -$3.19M derived: sum of 4 quarters · filed 2026-03-11 |
| 2024-10-31 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-09 | -$1.67M 10-Q · filed 2025-12-09 | -$2.57M derived: sum of 3 quarters · filed 2025-12-09 | -$2.41M derived: sum of 4 quarters · filed 2025-12-09 |
| 2024-07-31 | -$41.53K 10-Q · filed 2025-09-10 | -$942.93K derived: sum of 2 quarters · filed 2025-09-10 | -$782.56K derived: sum of 3 quarters · filed 2025-09-10 | $142.64K derived: sum of 4 quarters · filed 2025-09-10 |
| 2024-04-30 | -$901.40K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-22 | -$741.03K derived: sum of 2 quarters · filed 2025-07-22 | $184.17K derived: sum of 3 quarters · filed 2025-07-22 | $54.94K 10-K · filed 2025-07-22 |
| 2024-01-31 | $160.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-10 | $1.09M derived: sum of 2 quarters · filed 2025-03-10 | $956.34K 10-Q · filed 2025-03-10 | $1.18M derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-10-31 | $925.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-11 | $795.97K 10-Q · filed 2024-12-11 | $1.02M derived: sum of 3 quarters · filed 2024-12-11 | $3.02M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-07-31 | -$129.23K 10-Q · filed 2024-09-11 | $98.42K derived: sum of 2 quarters · filed 2024-09-11 | $2.09M derived: sum of 3 quarters · filed 2024-09-11 | $1.71M derived: sum of 4 quarters · filed 2024-09-11 |
| 2023-04-30 | $227.65K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $2.22M derived: sum of 2 quarters · filed 2024-07-30 | $1.84M derived: sum of 3 quarters · filed 2024-07-30 | $1.71M 10-K · filed 2024-07-30 |
| 2023-01-31 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-25 | $1.62M derived: sum of 2 quarters · filed 2024-03-25 | $1.48M 10-Q · filed 2024-03-25 | |
| 2022-10-31 | -$378.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-12-15 | -$514.73K 10-Q · filed 2023-12-15 | ||
| 2022-07-31 | -$136.23K 10-Q · filed 2023-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |